IBD: 粪钙卫蛋白水平可预测IBD患者肠道组织学缓解和内镜缓解率

2021-04-23 MedSci原创 MedSci原创

在过去的十年中,粘膜愈合成为了炎症性肠病(IBD)患者的治疗目标。达到MH的患者会有更好的长期预后,如复发风险降低,无类固醇缓解期延长,较少住院几率等。

      在过去的十年中,粘膜愈合成为了炎症性肠病(IBD)患者的治疗目标。达到MH的患者会有更好的长期预后,如复发风险降低,无类固醇缓解期延长,较少住院几率等。但是粘膜愈合的评判手段并不可靠,目前广泛使用的Mayo内镜评分(MES)并不是很好的预测工具。有18%–24%的内镜下愈合患者发现仍然存在组织学炎症。粪便钙卫蛋白(FC)是公认的但粘膜愈合(MH) 的间接的标志物。本项研究旨运用先进的内窥镜技术寻找内镜缓解(ER)和组织学缓解(HR)的最佳FC阈值。

 

      在这项横断面研究中,研究人员从76名UC和41名CD患者中收集了临床,内镜,组织学数据和FC浓度水平。创建接收器工作特征曲线,以评估FC的最佳截止值,从而通过UC患者的Mayo内镜评分(MES),溃疡性结肠炎内窥镜严重程度指数(UCEIS)和改良的PICaSSO(帕丁顿国际虚拟染色体内窥镜评分)评估ER CD患者的简单内镜评分(SES-CD)的有效性。

 

      研究结果显示在UC患者中,通过MES,UCEIS和改良的PICaSSO计算得出的用于识别ER的FC的最佳阈值分别为112、148和161 mcg/ g,准确度分别为86.9%,86.8%和81.6%。RHI和Nancy Index评分用来预测粘膜愈合的最佳FC值为112 mcg/g和172 mcg/g,准确度分别为84.2%和81.6%。

图:不同粪钙卫蛋白的截断值对于粘膜愈合的差异

      由此,作者得出结论:在UC患者中,预测ER的FC的最佳临界值为96 mcg/g,准确度为82.9%。最好用225 mcg/g的FC值预测粘膜愈合情况,准确度为75.6%。

 

 

原始出处:

Rosanna Cannatelli. Et al. Fecal Calprotectin Thresholds to Predict Endoscopic Remission Using Advanced Optical Enhancement Techniques and Histological Remission in IBD Patients. Inflammatory Bowel Diseases.2021.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1008044, encodeId=526e1008044e7, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161111/IMG5825824F0A19A1764.jpg, createdBy=edeb1422421, createdName=yxtcm.best, createdTime=Sun Aug 15 12:13:50 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926288, encodeId=a65f19262889a, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Thu Dec 30 08:41:31 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262237, encodeId=530e126223e19, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Apr 25 11:41:31 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263648, encodeId=5ce0126364824, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun Apr 25 11:41:31 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
    2021-08-15 yxtcm.best

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1008044, encodeId=526e1008044e7, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161111/IMG5825824F0A19A1764.jpg, createdBy=edeb1422421, createdName=yxtcm.best, createdTime=Sun Aug 15 12:13:50 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926288, encodeId=a65f19262889a, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Thu Dec 30 08:41:31 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262237, encodeId=530e126223e19, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Apr 25 11:41:31 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263648, encodeId=5ce0126364824, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun Apr 25 11:41:31 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1008044, encodeId=526e1008044e7, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161111/IMG5825824F0A19A1764.jpg, createdBy=edeb1422421, createdName=yxtcm.best, createdTime=Sun Aug 15 12:13:50 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926288, encodeId=a65f19262889a, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Thu Dec 30 08:41:31 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262237, encodeId=530e126223e19, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Apr 25 11:41:31 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263648, encodeId=5ce0126364824, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun Apr 25 11:41:31 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1008044, encodeId=526e1008044e7, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20161111/IMG5825824F0A19A1764.jpg, createdBy=edeb1422421, createdName=yxtcm.best, createdTime=Sun Aug 15 12:13:50 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1926288, encodeId=a65f19262889a, content=<a href='/topic/show?id=9238e767680' target=_blank style='color:#2F92EE;'>#组织学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77676, encryptionId=9238e767680, topicName=组织学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Thu Dec 30 08:41:31 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1262237, encodeId=530e126223e19, content=<a href='/topic/show?id=0ceb30545e0' target=_blank style='color:#2F92EE;'>#内镜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30545, encryptionId=0ceb30545e0, topicName=内镜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Apr 25 11:41:31 CST 2021, time=2021-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1263648, encodeId=5ce0126364824, content=<a href='/topic/show?id=75bc930217' target=_blank style='color:#2F92EE;'>#IBD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9302, encryptionId=75bc930217, topicName=IBD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc0372, createdName=bnurmamat, createdTime=Sun Apr 25 11:41:31 CST 2021, time=2021-04-25, status=1, ipAttribution=)]
    2021-04-25 bnurmamat

相关资讯

JCC: 存在肺功能受累的活动性IBD患者对生物治疗的反应差异

在溃疡性结肠炎(UC)患者的流行病学研究中,研究人员观察到因呼吸道疾病死亡率有增加的现象,这是潜在的被严重低估的炎症性肠病(IBD)肠外表现的影响。

JCC:饮食摄入模式与IBD患者发生疾病复发风险有关

目前已经有研究表明,饮食与炎症性肠病(IBD)的发作有关。多达一半的IBD患者认为饮食会导致疾病复发。

IBD: 炎性肠病患者门静脉血栓形成的发生风险分析

门静脉血栓形成(PVT)是炎症性肠病(IBD)的常见并发症,预后不佳。本项研究旨在试图更好地描述IBD患者出现PVT的危险因素,并比较不同的治疗方法及对于IBD相关PVT的预后。

GUT:炎症性肠病孕妇药物治疗对后代健康结果的长期影响

患有炎症性肠病的孕妇,在怀孕期间接受抗炎症性肠病药物治疗不会导致后代健康异常

GUT: 英夫利昔单抗治疗的IBD患者的抗新冠病毒的抗体反应会被减弱

新冠病毒(SARS-CoV-2)感染和/或接种疫苗后诱导保护性免疫对于抑制传播至关重要。

AP&T: 血清甲状腺素T3与甲状腺素T4(T3 / T4)的比值可预测老年IBD患者对生物疗法的治疗效果

老年炎症性肠病(IBDs)的发病率正在逐渐增加,并且老年对于目前的药物治疗方案有着与年轻人不一样的反应,因此,需要另外的生物标记物来优化其治疗方法。